Arkema is actively developing its new Kepstan® PEKK (Poly-Ether-Ketone-Ketone) ultra high performance polymer with applications in the fields of carbon fiber composites and 3D printing. Success in these fields has prompted Arkema to increase its production capacities in France now and in the United States in the near future.
Arkema reinforces its organic peroxide operations with the acquisition of Italian company Oxido, a European player in the formulation of organic peroxides used primarily in synthetic rubber crosslinking.
Arkema and Jurong Chemical announce today that they have concluded an agreement regarding the next steps of their cooperation in Acrylics in China. This agreement extends, until January 2016, the period for Arkema to exercise its call option to access a total of 320,000 t/year acrylic acid production capacity.
Effective 3 February 2015, Bernard Pinatel, currently CEO of Bostik, is being appointed a member of Arkema’s Executive Committee. He will succeed Pierre Chanoine who is retiring. Meanwhile, the structure of Arkema’s business segments is changing in the wake of the acquisition of Bostik.
Arkema finalized the acquisition of Bostik, the world’s no. 3 in adhesives, on 2 February. With this acquisition, the Group reaches a new milestone in its development, and confirms its ambition to become a world leader in specialty chemicals and advanced materials. Bostik’s growth prospects and the complementarities identified between the two groups will sustain the success of this high value creating project.
· First thiochemicals industrial platform in Asia
· Strengthening of Arkema’s world leading position in this product line
· Development in a fast growing region, in particular in the animal feed, petrochemicals and refining markets
Arkema has finalized the first stage of its acrylics assets acquisition project in Taixing, China, and now has access to a modern and competitive 160,000 t/year acrylic acid production capacity in Asia for the sum of US$ 240 million. This investment will enable the Group to serve its customers in China and in Asia in growing markets such as superabsorbents, paints, adhesives and water treatment.
• Proposed acquisition of Bostik, number 3 worldwide in adhesives and part of Total’s specialty chemicals
• New milestone in Arkema’s transformation in line with the Group’s strategy
- Reinforcing Arkema’s profile with the integration of a low cyclical and low capital-intensive activity with sales of €1.53 billion
- Strategic priorities well aligned: innovation, expansion in emerging countries and operational excellence
• High value creating project
- Significant potential for improving Bostik’s operating margin
- Well identified synergies
- Cash flow accretive from first full year and EPS accretive from second year
- Execution facilitated thanks to common culture
• Offer made on basis of €1.74 billion enterprise value (11 times EBITDA)
• A fully secured funding
As part of a plan to improve the profitability of its fluorogas business, on September 9th Arkema presented to the Zaramillo plant’s personnel representative bodies a project for the closure of fluorogas productions at its Spanish site.
The European fluorogas industry has been severely impacted for several years by a competitiveness gap with China and the United States. Hence the Zaramillo site is faced with this European environment as well as structural problems, which have prompted this proposed closure of the fluorogas productions.
As part of its procurement policy for strategic raw materials, Arkema has reached an agreement for the supply of propylene with Enterprise Products Partners L.P., a leading United States midstream Energy Company.
• €1,520 million sales, 3.3% down on 2Q’13 at constant business scope and exchange rate
• €206 million EBITDA (2Q’13 at €273 million)
- Continuing challenging market conditions in fluorogases
- Following a good 1st quarter, temporary unfavourable factors in polyamides and lower volumes than expected in acrylics
- Solid performance in the other product lines
• Good resilience of EBITDA margin at 13.6% in this temporary more challenging environment
• Further cost optimization plan of €50 million over next three years
• €1,106 million net debt, slightly down on end of June 2013
Arkema announces the start-up of its new plant for the production of methyl acrylate, an acrylic acid derivative used in the manufacture of polymers for water treatment, elastomers and engineering polymers. This investment, on its Clear Lake site in Texas, represents the last phase of a $110 M investment plan intended to strengthen Arkema’s rankings in the US acrylics market.
During Arkema’s Combined Annual General Meeting held on May 15th 2014 and chaired by Thierry Le Hénaff, Chairman and Chief Executive Officer of the Group, the shareholders, representing 63.19% of the voting rights, adopted by a very large majority all the resolutions approved by the Board of Directors.
CECA , Arkema’s Filtration and Adsorption subsidiary, and Saudi company Watan Industrial Investment have set up a joint venture, majority-owned by Arkema, which will operate an oilfield production chemicals blending plant and storage facility in Saudi Arabia. Based within the Dammam industrial city, the new site will enable CECA to meet the high demand for oilfield production chemicals in the Gulf region.
• €1,523 million sales, 0.7% up at constant exchange rate and scope of business
- Volumes 3.3% up
- -2.6% price / product mix effect mostly in fluorogases
• €213 million EBITDA, down 9% (7% up excluding fluorogases)
- EBITDA 19% up in High Performance Materials supported by volume growth
- Confirmation of good resilience of Coating Solutions in a mixed environment
- In Industrial Specialties, beginning of the year impacted by more challenging market conditions than last year in fluorogases
• 14.0% EBITDA margin
• €77 million net income Group share (Q1 2013: -€30 million)
• €1,007 million net debt stable compared to end March 2013
Corporate - Finance - Products - Social responsibility
The new electrolysis unit at Arkema’s Jarrie plant near Grenoble, France, inaugurated today, marks a new milestone in the site’s modernisation. This €100 m investment has enabled the facility to adapt to the latest regulations on industrial risks (‘PPRT’) and to convert its mercury electrolysis to the membrane technology, thereby pre-empting the mandatory deadline by several years.
Some 6,000 employees and former employees have subscribed for 491,502 shares totalling €31.5 million as part of the capital increase operation reserved for Arkema employees, which has just closed. Setting yet another record in terms of amount invested and number of participants, this latest operation is a reflection of the employees’ confidence in their Group’s strategy and prospects.